Literature DB >> 23383616

Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.

Faouzia Ajili1, Nadia Kourda, Amine Darouiche, Mouhamed Chebil, Samir Boubaker.   

Abstract

PURPOSE: Tumor-associated macrophages can regulate the growth of various cancers positively or negatively. Intravesical bacillus Calmette-Guerin instillation is now the gold standard treatment for bladder carcinoma in situ. The authors investigated the correlation between tumor-associated macrophages infiltrating bladder carcinoma in situ and the response to intravesical bacillus Calmette-Guerin therapy.
MATERIALS AND METHODS: The authors examined paraffin-embedded tissues from 41 patients with bladder carcinoma in situ who received intravesical bacillus Calmette-Guerin therapy. Tumor-associated macrophages were immunohistochemically stained by anti-CD68 monoclonal antibody.
RESULTS: The median number of tumor-associated macrophages infiltrating among cancer cells and the number in the lamina propria were 4 and 24, respectively. Recurrent carcinoma in situ was found in 4.8% of cases with a lower cancer cell tumor-associated macrophage count but in 47.6% of those with a higher cancer cell tumor-associated macrophage count (less than 4 vs. 4 or greater). Recurrence was found in 31.8% of patients with a lower lamina propria tumor-associated macrophage count but in 21.1% of those with a higher lamina propria tumor-associated macrophage count (less than 25 vs. 25 or greater). The median ratio of tumor-associated macrophages among cancer cells vs. in the lamina propria was 0.2. Recurrence-free survival was significantly better in patients with a lower cancer cell tumor-associated macrophage count (p = .0002). Those with a lower cancer cell-to-lamina propria tumor-associated macrophage ratio had a higher recurrence-free rate (p < .0001). Multivariate analysis revealed that the cancer cell tumor-associated macrophage count and the cancer cell-to-lamina propria tumor-associated macrophage ratio can be prognostic factors for bladder carcinoma in situ.
CONCLUSIONS: The count of tumor-associated macrophages infiltrating the cancer area is useful for predicting the response of bladder carcinoma in situ to intravesical bacillus Calmette-Guerin instillation before treatment initiation. Although on univariate analysis TAMs are associated with other poor prognosticators, on multivariate analysis, TAMs appear only to be associated with MI and VI. TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23383616     DOI: 10.3109/01913123.2012.728688

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  11 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

Review 3.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

Review 4.  Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Authors:  Johannes Mischinger; Eva Comperat; Christian Schwentner; Arnulf Stenzl; Georgios Gakis
Journal:  Curr Urol Rep       Date:  2015-09       Impact factor: 3.092

5.  A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.

Authors:  Meiying Zhang; Yifeng He; Xiangjun Sun; Qing Li; Wenjing Wang; Aimin Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2014-02-08       Impact factor: 4.234

6.  Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment.

Authors:  Yang Zhao; Degui Wang; Ting Xu; Pengfei Liu; Yanwei Cao; Yonghua Wang; Xuecheng Yang; Xiaodong Xu; Xinsheng Wang; Haitao Niu
Journal:  Oncotarget       Date:  2015-11-17

7.  Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer.

Authors:  Jingxian Li; Yantao Lou; Shuai Li; Fei Sheng; Shuaibing Liu; E Du; Zhihong Zhang
Journal:  Front Mol Biosci       Date:  2021-01-29

Review 8.  Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer.

Authors:  Lucien McBeth; Maria Grabnar; Steven Selman; Terry D Hinds
Journal:  Int J Endocrinol       Date:  2015-08-10       Impact factor: 3.257

9.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Authors:  Renate Pichler; Josef Fritz; Claudia Zavadil; Georg Schäfer; Zoran Culig; Andrea Brunner
Journal:  Oncotarget       Date:  2016-06-28

10.  Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.

Authors:  Shui-Qing Wu; Ran Xu; Xue-Feng Li; Xiao-Kun Zhao; Bin-Zhi Qian
Journal:  Oncotarget       Date:  2018-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.